The US FDA recently approved a new paliperidone formulation: Invega Trinza. This is a 3-month injection that allows a longer dosing interval.
In brief
- Brand name
- Invega Trinza
- Approval date
- May 18, 2015
- Indication
- Treatment of schizophrenia in patients after they have been adequately treated with 1-month paliperidone palmitate extended-release injectable suspension (Invega Sustenna) for at least four months
- Efficacy trial that led to FDA approval [1] :
- One randomized, multicenter trial
- N=506 patients
- Main outcome : time to relapse
Prescribing information
- Use Invega Trinza only after the patient has been adequately treated with the 1-month paliperidone palmitate extended-release injectable suspension for at least four months
- Should be administered once every 3 months.
Initiate INVEGA TRINZA™ when the next 1-month paliperidone palmitate dose is scheduled with an INVEGA TRINZA™ dose based on the previous 1-month injection dose as shown below.
| If the last dose of Invega Sustenna is: | Initiate Invega Trinza at the following dose: |
|---|---|
| 78 mg | 273 mg |
| 117 mg | 410 mg |
| 156 mg | 546 mg |
| 234 mg | 819 mg |
Paliperidone is a second-generation antipsychotic. It has affinity for D2, 5HT2A, alpha 1 and alpha 2 receptors
References
- Berwaerts, J., Liu, Y., Gopal, S., Nuamah, I., Xu, H., Savitz, A., … & Hough, D. W. (2015). Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial. JAMA psychiatry
- Invega Trinza (paliperidone palmitate) extended-release injectable suspension. [Prescribing Information]. Titusville, NJ Janssen Pharmaceuticals, Inc. Accessed May 2015
